←
Loading live data…
$ABBV$288.24 ▼2.2%
AbbVie Inc.
WHAT THEY DO
AbbVie is a biopharmaceutical company that discovers, develops and sells prescription medicines, led by its immunology franchise (Humira, Skyrizi, Rinvoq) plus neuroscience, oncology and aesthetics (Botox). It makes money by selling branded drugs to patients, insurers and health systems worldwide.
💎 CONVERGENCE PLAY — in 2 themes
GLP-1 & ObesityImmunologyNeuroscience
PRICE
Loading…
REVENUE MIX
Immunology45%
Neuroscience20%
Oncology12%
Aesthetics13%
Other/Allergan legacy10%
COST
COGS26%
R&D14%
SG&A20%
Op Margin40%
FINANCIAL HEALTH
Reported through Sep 30, 2026
Figures are trailing twelve months (TTM) unless marked otherwise.
REVENUE
$66.0B
Growth
10%
QTR YOY
Gross M.
74%
P/E
49.5
EV/EBITDA
18.2
Net M.
16%
FCF M.
27%
D/E
20.19
LATEST QTR
Op M.
40%
PLUG INTO YOUR DCF
Historical growth
6%
Analyst 5y growth
—
Forward P/E
17.8
PEG ratio
0.60
Trailing EPS
$5.80
Forward EPS
$16.20
Multiple compressing
Forward P/E is lower than trailing — earnings are expected to grow into the price.
CAPEX & R&D — LAST 0 FISCAL YEARS (SEC FILINGS)
Loading…
TAM
SIZE
$1.6T by 2030
CAGR
6%
Global prescription pharma spend is roughly $1.6T and growing mid-single digits, driven by aging populations, immunology and obesity/GLP-1. AbbVie competes in high-value specialty niches where pricing power is strong but patent cliffs and payer pressure cap long-run growth.
RISK ASSESSMENT
HIGSkyrizi/Rinvoq concentration: these two drugs now drive most growth and face eventual loss of exclusivity and rising competition.
MEDPayer and IRA drug-price negotiation pressure plus Humira biosimilar erosion weigh on US pricing.
LOWPipeline/clinical trial failures or Allergan aesthetics softness could trim estimates.
🐂 BULL
Skyrizi and Rinvoq are compounding fast enough to more than offset Humira erosion, and a deep neuroscience/obesity pipeline plus Botox give AbbVie durable mid-single-digit growth with 74% gross margins.
🐻 BEAR
At ~49x trailing earnings and 18x EBITDA the stock already prices in flawless execution, leaving little cushion if immunology growth decelerates or drug-pricing policy bites.
EARNINGS
EPS · Q3 2026
Beat ✓
REVENUE
Beat ✓
MANAGEMENT TONE
BearishBullish
🔗 IMPACT ON YOUR THESIS
Skyrizi/Rinvoq offset Humira cliff
On Track→On Track
Immunology growth of ~10% YoY confirms the transition is on track.
Neuroscience & obesity pipeline optionality
Watch→Watch
Early-stage data encouraging but no near-term revenue contribution.
Valuation leaves little margin of safety
Watch→Watch
Beat-and-raise supports estimates but multiple stays rich at ~49x.
AI-powered data, computed by TreasureX · May contain inaccuracies
⚠️
All values, scores, and figures here are computed from your own assumptions and public data, for educational purposes only. This is not investment advice — TreasureX does not recommend buying or selling any security. Results change with your inputs. Please do your own research and use your own judgement before making any investment decision.